E-Learning Center
Join Our Network
OncoFacts

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

LM GSK symposium


 

OVERCOMING RITUXIMAB RESISTANCE:
THE EMERGING ROLE OF NEXT GENERATION
ANTI-CD20 ANTIBODY THERAPIES IN B-CELL LYMPHOMAS
A Satellite Symposium at Lymphoma & Myeloma 2008: International Congress on Hematologic Malignancies

Saturday, October 18, 2008

New York, New York

Waldorf=Astoria

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 1.50 of AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Who Should Attend

This educational activity is specifically designed for hematologists, internists, oncologists, and other physicians, physicians-in-training, and other healthcare professionals (nurse practitioners, physician assistants, nurses, pharmacists) interested and/or involved in the care of patients with lymphoma and myeloma.


Objectives

After successful completion of this educational activity, attendees should be able to:

  • Describe the limitations of, and acquired resistance to, rituximab in patients with B-cell lymphomas
  • Implement the best available regimens for patients with relapsed/refractory B-cell lymphomas
  • Evaluate efficacy, toxicity and safety of the next generation anti-CD20 therapies for patients with B-cell lymphomas
  • Discuss current trials and remaining questions these and future trials must address for improving outcomes in patients with B-cell lymphomas

Myron S. Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York


Peter W.M. Johnson, MD,FRCP

Southampton General Hospitale
Southampton, United Kingdom


Brian K. Link, MD

Department of Internal Medicine
Holden comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa

 

 

Saturday, October 18, 2008

12:00 PM
Welcome

12:05 PM
Understanding rituximab resistance
Myron S. Czuczman, MD

12:25 PM
Current options for relapsed/refractory B-cell lymphomas
Peter W.M. Johnson, MD, FRCP

12:45 PM
Next generation anti-CD20 therapies for overcoming resistance in patients with B-cell lymphomas
Brian K.Link, MD

1:05 pm
Clinical trials in 2008 and beyond: Remaining questions
John P. Leonard, MD

1:25 pm
Chair summary and take home points

1:30 pm
Adjourn

 

Registration is complimentary to attendees of the Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies

Waldorf=Astoria
The Starlight Room
New York, New York

Moderator:
John P. Leonard, MD
Center for Lymphoma Myeloma
Weill Medical College of Cornell University
New York, New York


ORGANIZER

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

PDF Announcement

This meeting is made possible thanks to an unrestricted educational grant from

Wyeth

Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.